TerThera b.v.

Live from Rotterdam! Specialists from the field of #Radiobiology are presenting their work during the #IWRMR2025 on the fundament of the radionuclide-based therapies which is instrumental to understanding the biology behind radioligand therapy (RLT), exploring new pathways for future treatment optimization and discuss the significant impact of #Terbium161 on a new level. Thank you Julie Nonnekens and Bart Cornelissen for the invitation to attend the 3rd International Workshop on Radiobiology of Molecular Radiotherapy. Also on behalf of attendees Imke Boekestijn and Stuart Chalk.

The #Nuklearmedizin2025 conference in Bremen has been kicked off today. Stop by our booth for a coffee and stay to discuss your #Terbium161 supply! Joined by our partners Van Overeem Nuclear b.v. and Zereau BV Philippe van Overeem Nicole Van Roozendaal Amandine Delva Stuart Chalk

TerThera will be present during the 63rd Annual Meeting of the German Society for Nuclear Medicine in Bremen, Germany, April 2-5. Join us at booth E1.8 for the latest news on #Terbium161 and how we can provide #Tb161 for your site. DEUTSCHE GESELLSCHAFT FÜR NUKLEARMEDIZIN e.V. #DGN2025 #Theranostics #Nuklearmedizin #NuclearMedicine #Theranostics #Radiopharmaceuticals #ProstateCancer

“Breaking News in Cancer Care!!!” We are proud to announce that Sarvodaya Hospital, Faridabad has become the *FIRST* Theranostics center in India to offer Terbium-161 PSMA therapy for prostate cancer treatment!!! This cutting-edge nuclear therapy represents a significant milestone in cancer care, offering new hope to patients with advanced metastatic castration resistant / hormone refractory prostate cancer. Our team of experts is dedicated to providing the highest quality care, and we are thrilled to bring this innovative treatment option to India. Join us in celebrating this achievement and taking a step forward in the fight against Prostate cancer!!! For more details please log in to our dedicated Theranostics website www.theranos.care Big shout out to my team Dr malasani vindhya Kamal Yadav @Shivani Khatana Niraj Singh @Dinesh Pandey @Rajkamal Parashar Indebted to Oncology team at Sarvodaya Healthcare for their unwavering support Dinesh Pendharkar. MD PhD FASCO Dr. Abhishek Raj Dr. Vishnu Hari Naveen Sanchety udbhav kathpalia Dr Col ASHOK KUMAR Dr Divya Gupta Special thank you note to dear Habibollah Dadgar Priya Ashok and Taranjit Singh for their useful insights Last but not the least, thanks to TerThera b.v. and B J Madan Co for technical and logistic support #TerbiumPSMA #ProstateCancer #Theranostics #RadioTheranostics #PSMATheranostics #CancerCare #IndiaFirst #MedicalBreakthrough #Oncology #HealthcareInnovation #SarvodayaHealthcare #SarvodayaCancerInstitute #DrSwagatDash

Today the conference #ALASBIMN took off in Cancún, Mexico. Join the conversation at booth #50 with Philippe van Overeem and Stuart Chalk on the impact of Terbium-161 within the field of Nuclear Medicine. #LATAM #Tb161 #Terbium161

Today, we performed our first-ever PSMA-targeting radioligand therapy with Terbium-161 (¹⁶¹Tb-PSMA). It’s likely to be the very first one in the whole of Europe in outpatient mode.   With its unique radiation profile, ¹⁶¹Tb offers new hope for those who have exhausted all other treatment options. Stay tuned for the results.   This marks a major milestone in bringing next-generation targeted therapy to patients with metastatic prostate cancer. We extend our gratitude to medisynt & TerThera b.v. for providing the high-quality Terbium-161, making this groundbreaking therapy possible!

Congratulations on another monumental achievement for Lagos Nuclear Medicine Department LMC! It is truly remarkable to be the first center in Nigeria, and the second country in Africa, to administer and offer the groundbreaking Terbium-161 cancer treatment. This cutting-edge therapy, with its unique beta-decay (6.95 days) and production process, not only provides gamma emissions for post-therapy SPECT imaging but also enhances treatment with additional auger emissions. The ability to target micrometastatic disease, delivering approximately 3.5 times the radiation dosage to the cells while ensuring that smaller cells receive radiation equivalent to larger ones, marking a significant advantage in cancer treatment. Thank you, TerThera b.v. for your unwavering support, outstanding production, and remarkable efforts in ensuring timely delivery. Your dedication is greatly appreciated! I am deeply grateful for this extraordinary blessing and for the Lord’s guiding hand in making these advancements possible. TerThera b.v. Loveworld Medical Centre Umhlanga Molecular Imaging and Therapy Masha Maharaj Samantha Du Plessis Trisha Govender Oluwapelumi Adekola Olapade Dolapo Oreoluwa Olasoju Desmond Mamah Anjolaoluwa Akinyemi #Terbium-161 #Cancer #Theragnostics #Treatment #Radionuclidetherapy #NuclearMedicine

Milestone reached. With the extended geographical reach, we were able to meet the demand for Terbium-161 (Tb-161) on 6 continents by ramping up the production that has led to reaching the threshold 200Ci or 7.4TBq Terbium-161 produced and expedited. #Terbium161 #Tb161 #161Tb

Please give a warm welcome to our newest member of the TerThera b.v. team, Imke Boekestijn! Imke will have an instrumental role as Quality and Validation Engineer to further strengthen the #Terbium161 platform, safeguarding the highest level of quality and preparing our processes for the next scale-up phase. “Amazing to join TerThera in such a significant role and to experience the impact of a novel and groundbreaking radionuclide, both from an academic and industrial perspective,” said Imke Boekestijn, Quality and Validation Engineer at TerThera.

Grab your agenda! During the first half of 2025 TerThera b.v. will be present at various events within the field of Nuclear Medicine. Visit us at any of the following events to discuss your supply of #Terbium161 and how we can support your initiatives! Asociación Latinoamericana de Sociedades de Biología y Medicina Nuclear (ALASBIMN) in Benito Juárez, Quintana Roo, Mexico, March 13-16, 2025.   63rd Annual Conference of the DGN Deutsche Gesellschaft für Nuklearmedizin e. V. in Bremen, Germany, April 2-5, 2025   International Conference on Nuclear Medicine and Medical Applications  (#ICNMMA) in Dubai, April 19, 2025 International Symposium on Radiopharmaceutical Sciences (#iSRS) Gold Coast in Queensland, Australia, May 11-15, 2025   Belgian Association of Nuclear Medicine (BELNUC Association) in Brugge, Belgium, May 16-18, 2025   Australian and New Zealand Society of Nuclear Medicine (#ANZSNM) in Melbourne, Australia, May 23-25, 2025 Annual conference Society of Nuclear Medicine and Molecular Imaging (SNMMI) in New Orleans, USA, June 21-25, 2025